yahoo_financeOriginal article
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
Phase 2EIK1001Positive
AI Analysis
Summary
Eikon Therapeutics announced dose selection for EIK1001 in the ongoing adaptive Phase 2/3 TeLuRide-006 trial for advanced melanoma treatment.
Clinical Trial Data
Phase
2/3
Outcome Details
Dose selection announced for TeLuRide-006 trial
Importance:5/10
Sentiment:
0.30
clinical_trialdose_selectionmelanomaadaptive_trial
Related Companies
Read the original article
Published by yahoo_finance on August 11, 2026 11:30 AM